Posts by Sandra Ansanay-Alex
La Tour Hospital Partners with Evidone
La Tour Hospital announces the launch of a pilot partnership with Evidone SA, a Swiss Health Valley healthcare technology company that develops computer vision and artificial intelligence solutions for hospital sterilisation departments and operating theatres. The aim of this partnership is to deploy and evaluate Evidone SA’s technology in real-world clinical settings, with a view…
Read MoreFluoSphera Partners with Debiopharm and Leica Microsystems
A new meaningful partnership in the Swiss Health Valley! FluoSphera licenses Debiopharm’s AbYlink™ Technology for 3D antibody characterization while leveraging Leica Microsystems Viventis deep imaging capabilities. The New license agreement enables an integrated workflow combining antibody labeling, human-relevant 3D testing and quantitative imaging for antibody-based therapeutics Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical…
Read MoreBruker expands its collaboration with Atinary and makes a minority investment
Bruker Corporation (NASDAQ:BRKR) announced that it is expanding its strategic collaboration with Atinary Technologies Inc., and acquiring a minority stake in the Lausanne-based company. The financial terms of the deal were not disclosed, according to the press release. This collaboration aims to integrate Chemspeed’s laboratory automation platforms, Bruker’s analytical instruments and SciY’s scientific software into…
Read MoreSwiss Gender Medicine Symposium
The Swiss Gender Medicine Symposium is taking place on 26 and 27 October 2026 at the Kursaal Bern Gender medicine has long since answered the question of whether biological sex and gender play a role. The evidence is there. What remains is the more difficult task: translating this knowledge into clinical practice, research structures, and…
Read MoreAlcon Halts Intraocular Lens Programmes After $402 Million Writedown
Alcon, the Geneva-based global leader in eye care, announced on Monday evening that it is discontinuing its intraocular lens (IOL) programmes, technology it acquired through the 2019 purchase of PowerVision for $285 million. These lenses were primarily designed for use in cataract surgery, replacing the eye’s clouded natural lens. Alcon has its global headquarters in…
Read MoreSICTIC Investors Day at FONGIT
The SICTIC Investor Day at Fongit is taking place on 24 September 2026 in Plan-les-Ouates. On 24 September 2026, join SICTIC at FONGIT in Geneva for an Investor Day, where groundbreaking startups meet forward-thinking investors. This event, hosted at Geneva’s premier innovation incubator, is ideal for those looking to discover new ideas and network with…
Read MoreEureka Biotech
Apply before 25 September 2026 for the Eureka Biotech programme, in collaboration with Innosuisse Project applications with a clear innovation content and implementation plan in biotech areas like medicine, bioinformatics, pharmaceutical products and services, life sciences, digitalization, (bio)process technology (non-exhaustive list of cooperation areas) are welcome. Check call outline for topics and scope. The countries…
Read MoreOculis Secures FDA Backing and Full Ownership of Privosegtor
Oculis Holding AG, a Zug-based biopharmaceutical company with operations in Lausanne, has had a decisive first two weeks of August 2026, combining positive US regulatory feedback with a strategic acquisition that together strengthen its position in neuro-ophthalmology. Positive FDA pre-IND feedback for acute MS relapses On August 3, Oculis announced that the FDA’s Division of…
Read MoreTimeline Wins $5.3 Million Court Judgment Against Fake Urolithin A Sellers
Timeline (Amazentis SA), the Lausanne-Based life-sciences company behind the postbiotic ingredient Urolithin A and its branded form Mitopure®, has secured a major legal victory in the United States. On July 15, 2026, the U.S. District Court for the District of Massachusetts permanently banned 19 online sellers from marketing or selling fraudulent Urolithin A products and…
Read MoreHAYA Therapeutics granted Fast Track designation by the FDA for HTX-001
HAYA Therapeutics SA, a clinical-stage biotechnology company based in Lausanne and San Diego, announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to HTX-001, its therapeutic candidate for symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). HTX-001 is an antisense oligonucleotide designed to reduce the expression of *WISPER*, a cardiac stress-specific long non-coding…
Read More